Annual EBITDA
-$741.79M$365.63M-97.20%
Summary
- Current Value
- As of today, RNA annual EBITDA is -$741.79M, down -97.20% on
- Historical Performance
- RNA annual EBITDA is down -317.85% over the past 3 years, down -1589.58% over the past 5 years
- All-Time High Comparison
- RNA annual EBITDA is currently -7233.58% below its historical high of -$10.12M set on
- 3-Year Low Comparison
- RNA annual EBITDA is at its 3-year low
- Sector Comparison
- RNA annual EBITDA is higher than 0.71% of companies in Healthcare sector
EBITDA Chart
SUGGESTED SERIES
Performance
| Metric | Date | Value | 1Y | 3Y | 5Y | 15Y |
|---|---|---|---|---|---|---|
| Annual EBITDA | -$741.79M | -97.2% | -317.9% | -1589.6% | -7233.6% | |
| Quarterly EBITDA | -$6.28M | -4259.0% | +89.0% | +78.4% | -210.7% | |
| TTM EBITDA | -$74.66M | -181.5% | +65.8% | +21.6% | -3596.1% | |
| Price | $6.98 | – | – | – | – | |
| PE Ratio | - | – | – | – | – | |
| Annual Revenue | $18.62M | +70.8% | +101.8% | +174.3% | +4812.4% | |
| Annual EPS | -$2.89 | -97.0% | +13.3% | -41.3% | -867.4% | |
| -$745.94M | -96.8% | -316.9% | -1584.7% | -7005.6% | ||
| Annual Net Income | -$49.50M | -97.0% | +71.5% | -11.6% | -341.3% |
EBITDA Highs
| Period | High | Date | Current |
|---|---|---|---|
| 3Y | -$177.53M | N/A | -317.9% |
| 5Y | -$43.90M | N/A | -1589.6% |
| All | -$10.12M | -7233.6% |
EBITDA Lows
| Period | Low | Date | Current |
|---|---|---|---|
| 3Y | -$741.79M | at low | |
| 5Y | -$741.79M | at low | |
| All | -$741.79M | at low |
EBITDA History
| Year | Value | Change |
|---|---|---|
| -$741.79M | -97.2% | |
| -$376.16M | -61.1% | |
| -$233.50M | -31.5% | |
| -$177.53M | -51.2% |
| Year | Value | Change |
|---|---|---|
| -$117.41M | -167.4% | |
| -$43.90M | -162.3% | |
| -$16.74M | -65.4% | |
| -$10.12M | - |
FAQ
- What is the current annual EBITDA of RNA?
- As of today, RNA annual EBITDA is -$741.79M
- What is 1-year change in RNA annual EBITDA?
- RNA annual EBITDA is down -97.20% year-over-year
- What is 3-year change in RNA annual EBITDA?
- RNA annual EBITDA is down -317.85% over the past 3 years
- How far is RNA annual EBITDA from its all-time high?
- RNA annual EBITDA is currently -7233.58% below its historical high of -$10.12M set on December 31, 2018
- How does RNA annual EBITDA rank versus sector peers?
- RNA annual EBITDA is higher than 0.71% of companies in Healthcare sector
- When is RNA next annual earnings release?
- The next annual earnings release for RNA is on
EBITDA Formula
EBITDA = Net Income + + +
Quarterly EBITDA
-$6.28M$16.00M+71.82%
Summary
- Current Value
- As of today, RNA quarterly EBITDA is -$6.28M, up +71.82% on
- Historical Performance
- RNA quarterly EBITDA is down -4259.03% year-over-year, up +89.05% over the past 3 years
- All-Time High Comparison
- RNA quarterly EBITDA is currently -4259.03% below its historical high of -$144.00K set on
- 3-Year Low Comparison
- RNA quarterly EBITDA is +93.56% above its 3-year low of -$97.42M reached on
- Sector Comparison
- RNA quarterly EBITDA is higher than 39.94% of companies in Healthcare sector
Performance
| Metric | Date | Value | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|
| Quarterly EBITDA | -$6.28M | +71.8% | -4259.0% | +89.0% | +78.4% | |
| Annual EBITDA | -$741.79M | – | -97.2% | -317.9% | -1589.6% | |
| TTM EBITDA | -$74.66M | -8.9% | -181.5% | +65.8% | +21.6% | |
| Price | $6.98 | -49.1% | – | – | – | |
| PE Ratio | - | – | – | – | – | |
| Quarterly Revenue | $15.32M | +410.0% | +24.2% | +443.7% | +608.3% | |
| Quarterly EPS | -$0.26 | +78.0% | -10000.0% | +63.2% | +61.6% | |
| -$6.63M | +70.7% | -3012.2% | +88.7% | +77.4% | ||
| Quarterly Net Income | -$4.27M | +78.9% | -10000.0% | +91.8% | +85.4% |
Quarterly EBITDA Highs
| Period | High | Date | Current |
|---|---|---|---|
| 1Y | -$144.00K | N/A | -4259.0% |
| 3Y | -$144.00K | -4259.0% | |
| 5Y | -$144.00K | -4259.0% | |
| All | -$144.00K | -4259.0% |
Quarterly EBITDA Lows
| Period | Low | Date | Current |
|---|---|---|---|
| 1Y | -$28.98M | +78.3% | |
| 3Y | -$97.42M | +93.6% | |
| 5Y | -$97.42M | +93.6% | |
| All | -$97.42M | +93.6% |
Quarterly EBITDA History
FAQ
- What is the current quarterly EBITDA of RNA?
- As of today, RNA quarterly EBITDA is -$6.28M
- What is RNA quarterly EBITDA most recent change?
- RNA quarterly EBITDA was up +71.82% on September 30, 2026
- What is 1-year change in RNA quarterly EBITDA?
- RNA quarterly EBITDA is down -4259.03% year-over-year
- How far is RNA quarterly EBITDA from its all-time high?
- RNA quarterly EBITDA is currently -4259.03% below its historical high of -$144.00K set on September 30, 2025
- How does RNA quarterly EBITDA rank versus sector peers?
- RNA quarterly EBITDA is higher than 39.94% of companies in Healthcare sector
- When is RNA next earnings release?
- The next earnings release for RNA is on
EBITDA Formula
EBITDA = Net Income + + +
TTM EBITDA
-$74.66M$6.13M-8.95%
Summary
- Current Value
- As of today, RNA TTM EBITDA is -$74.66M, down -8.95% on
- Historical Performance
- RNA TTM EBITDA is down -181.52% year-over-year, up +65.76% over the past 3 years
- All-Time High Comparison
- RNA TTM EBITDA is currently -3596.09% below its historical high of -$2.02M set on
- 3-Year Low Comparison
- RNA TTM EBITDA is +76.82% above its 3-year low of -$322.04M reached on
- Sector Comparison
- RNA TTM EBITDA is higher than 22.14% of companies in Healthcare sector
Performance
| Metric | Date | Value | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|
| TTM EBITDA | -$74.66M | -8.9% | -181.5% | +65.8% | +21.6% | |
| Annual EBITDA | -$741.79M | – | -97.2% | -317.9% | -1589.6% | |
| Quarterly EBITDA | -$6.28M | +71.8% | -4259.0% | +89.0% | +78.4% | |
| Price | $6.98 | -49.1% | – | – | – | |
| PE Ratio | - | – | – | – | – | |
| TTM Revenue | $38.82M | +8.3% | +87.2% | +283.0% | +303.7% | |
| TTM EPS | -$4.11 | -6.7% | -120.8% | -37.6% | -68.1% | |
| -$75.63M | -9.3% | -182.4% | +66.0% | +21.1% | ||
| TTM Net Income | -$70.22M | -6.4% | -120.3% | +65.3% | +26.7% |
TTM EBITDA Highs
| Period | High | Date | Current |
|---|---|---|---|
| 1Y | -$26.52M | N/A | -181.5% |
| 3Y | -$26.52M | -181.5% | |
| 5Y | -$26.52M | -181.5% | |
| All | -$2.02M | -3596.1% |
TTM EBITDA Lows
| Period | Low | Date | Current |
|---|---|---|---|
| 1Y | -$74.66M | at low | |
| 3Y | -$322.04M | +76.8% | |
| 5Y | -$322.04M | +76.8% | |
| All | -$322.04M | +76.8% |
TTM EBITDA History
FAQ
- What is the current TTM EBITDA of RNA?
- As of today, RNA TTM EBITDA is -$74.66M
- What is RNA TTM EBITDA most recent change?
- RNA TTM EBITDA was down -8.95% on September 30, 2026
- What is 1-year change in RNA TTM EBITDA?
- RNA TTM EBITDA is down -181.52% year-over-year
- How far is RNA TTM EBITDA from its all-time high?
- RNA TTM EBITDA is currently -3596.09% below its historical high of -$2.02M set on March 31, 2019
- How does RNA TTM EBITDA rank versus sector peers?
- RNA TTM EBITDA is higher than 22.14% of companies in Healthcare sector
- When is RNA next earnings release?
- The next earnings release for RNA is on
EBITDA Formula
EBITDA = Net Income + + +
Data Sources & References
- RNA Official Website www.atriumtherapeutics.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1599901/000159990126000031/0001599901-26-000031-index.htm
- RNA Profile on Yahoo Finance finance.yahoo.com/quote/RNA
- RNA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rna
